Press Room

Press Clipping / Nov 12, 2018

How Hovione grew from a basement lab to a global pharmaceutical services company

C&EN, November 12, 2018

Global Pharmaceutical Services Diane Villax Guy Villax | Hovione

Diane Villax poses in 1962 with her husband, Ivan (left), and this year with her son, Guy, in front of the house, Guy’s current home, where she and Ivan launched Hovione in 1959.

 

 

Diane Villax, Hovione’s still-active matriarch, recounts the rise of the pioneering firm

He started, the poor chap, at the age of 23,” recalls Diane Villax of her son Guy’s debut in 1984 at Hovione, the family’s pharmaceutical chemical business. “He was thrown to the lions in the Far East. To China. He was told by his father, ‘Build me a factory in Macau. Get me some land, talk to the authorities, and build me a factory.”

This he did, she says. “He built it in 14 months, ran it for six months, and asked for an FDA inspection.”

Still marveling at the audacity of the project, Diane recounts the many roadblocks to building a factory in Macau, a former Portuguese colony, now a Las Vegas-like gaming resort, where no construction engineers were up to the project in 1984. Shipping construction materials, glass-lined tanks, and other apparatuses from Italy, Greece, and the company’s home base of Lisbon was another daunting challenge, given that the only suitable cargo port was in Rotterdam, the Netherlands.

Her daughter, Sofia, was also deployed to China, in charge of quality control at the new plant. Diane remembers Sofia calling home rattled after an interview with an inspector who brusquely dismissed the upstart plant’s chances of passing a U.S. Food & Drug Administration audit. “Poor child,” she says. “Well, they had the inspection, and it was fine, so then they all celebrated.”

Over a Saturday lunch of boiled prawns and salad on the patio of her home in a Lisbon suburb, Diane shares several other anecdotes of how she and her husband, the chemist Ivan Villax, started a company in their basement, developing fermentation processes for the manufacture of antibiotics. It has evolved over 59 years to become a major supplier of drug ingredients and associated services, with factories on three continents.

Ivan died in 2003, but at 83 Diane remains active with Hovione. She is a board member, having stepped down as chair only two years ago. Guy and Sofia are also on the board, along with four outside nonexecutive directors, including the current chair. Passing the chair to an outsider, Diane says, seemed like the thing to do now that the company has achieved a critical mass.

 

Born in Portugal but raised in England—her mother Portuguese, her father British—Diane Du Boulay met Ivan, a Hungarian chemist displaced by the Russian invasion after World War II, in 1956. Both their families had moved to Lisbon. Ivan came from France, where he studied microbiology, developing chemistry for penicillin, tetracycline, and other antibiotics in his spare time.

“I think he got his first patent in 1955,” Diane recalls. “He was enjoying life in Lisbon. A young man about town and a scientist and a bit of a magician at dinner parties. He was very much in demand.”

The two married and started the company with two partners, both of whom left shortly thereafter. Diane and Ivan began by selling antibiotics and other generic drugs, achieving their first big success selling betamethasone in Japan. They built a manufacturing plant on land his family owned outside Lisbon in Loures.

“Ivan was obviously the inventor, the producer, and the salesman,” she says. “Somebody had to look after the back office, issue invoices, talk to the banks, and get some money. So that was me. For 35 years, nobody signed a check except for me. I was in charge of all the imports and exports and all the licenses.”

The focus remained on generics, Diane says, until Guy came back from an InformEx exposition in the U.S. in 1993, enthusiastic about exclusive synthesis of active pharmaceutical ingredients (APIs). They got a call from Bristol-Myers Squibb shortly thereafter with a request to make an API, found a chemical engineer willing to take on the complicated chemistry, and never turned back.

Nor has Diane disengaged from oversight of the company’s business, which in one famous instance involved direct engagement with a chemical.

Early on, with Ivan on the road, Diane was awakened one night by a chemical smell in the house. She called an engineer who worked for the company, and the two identified a leaking vessel in the basement. They found an empty container. Preparing to transfer the contents of the vessel, Diane realized that someone would have to suck on the hose to get the liquid moving. The engineer demurred, noting that they had no idea what was leaking.

“I had to do it,” she says. “Somebody had to get it going.” The operation was a success, and Diane soon learned that the solvent was ethyl acetate. “My husband was rather horrified when he learned of this.”

Diane Villax was awarded Portugal’s Scientific Merit Medal at the opening of Science 2017, a science and technology meeting in Lisbon. The medal is given in recognition of contributions to the development of science and scientific culture in Portugal.

 

Read the article at C&EN online

 

 

Also in the Press Room

See All

The new company, which will be located in Portugal, will focus on the development of drug delivery solutions for emerging drug modalities. Cell and gene therapies represent a paradigm shift in modern medicine, offering unprecedented opportunities to address previously untreatable diseases. ViSync solutions will help address some of the manufacturing challenges caused by the complex nature of new modalities, with special focus on stabilization, cell or tissue targeting and drug payload delivery.  Lisbon, 9th May 2024 – The specialist integrated CDMO and leader in pharmaceutical spray drying and particle engineering, and iBET (Instituto de Biologia Experimental e Tecnológica), a private not-for-profit research intensive SME in the area of Biotechnology and Life Sciences, today announced the creation of ViSync Technologies, a new joint venture located in Oeiras, close to Lisbon. The newly formed company will focus on developing innovative technologies and scalable solutions to help pharmaceutical companies address formulation and manufacturing challenges in transformative cell and gene therapies. Hovione has a strong track record in industrializing new technologies and supporting Pharma Companies with their clinical and commercial volume manufacturing needs, while iBET has a strong biological background and a global reputation for its scientific knowledge of the new therapeutic modalities space, particularly cell and gene therapy.  New modalities, such as gene and cell therapies, RNA drugs and other complex biologics, are a rapidly growing segment of the pharmaceutical industry. They promise to bring breakthroughs to the treatment of a wide range of diseases and conditions, including cancer, genetic disorders, rare diseases and neurological conditions.  While this rapid growth has been driven by remarkable efficacy in addressing unmet clinical needs, the complex nature of the new modalities brings challenges, including limited drug administration options, immunogenic responses and off-target effects, issues with high dose delivery and high costs. The poor stability of these drugs is also an issue, resulting in the need for cold supply chains. ViSync will aim to develop novel technology platforms to address the unmet needs of pharmaceutical customers developing these transformative new products. “The creation of ViSync in collaboration with iBET marks an exciting new chapter in Hovione´s commitment to innovation”, said Dr Jean-Luc Herbeaux, Hovione´s CEO. “New therapeutic modalities have the potential to bring radical improvements to current standards of care and we are thrilled to partner with iBET, a world-renowned expert organization in this area, to develop technology platforms that help customers bring transformative therapies to patients worldwide. The first step will be to assemble a team who possesses the knowledge, expertise, and ingenuity needed to navigate the complexities ahead." “The establishment of ViSync in partnership with Hovione represents a pivotal moment in iBET’s dedication to pioneering research in advanced therapies,” stated Dr. Paula Alves, iBET’s CEO. “The immense promise of these new modalities is at our reach and we are delighted to join forces with Hovione, a globally recognized leader in technological industrialization and drug delivery. In this common endeavor, we will gather the scientific and technical competences and skills to support our clients and partners in delivering groundbreaking therapies to patients globally.” ViSync will develop its own lab facility in Lisbon and expects to be able to start its research and development work by the end of 2024.   About Hovione Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) it has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and manufacturing, capsule filling and devices.     Hovione's culture is based on innovation, quality and dependability. Hovione is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.   About iBET iBET is a private non-profit institution devoted to biotechnology research, with 35 years of experience creating and transferring knowledge to the global biopharma and biotech sectors. iBET’s core expertise lies on the development of bioprocessses and analytical tools for Advanced Therapeutic Medicinal Products (ATMPs), including cell and gene therapies, vaccines, antibodies and other innovative therapeutic products. Leveraged by the emerging areas of Data Science and Translational Immunology, we offer bespoke R&D services from early-stage R&D to GMP manufacturing.  iBET’s infrastructure comprises cutting-edge laboratories, a GMP certified Analytical Services Unit, and a Late-Stage R&D and Bioproduction Unit, covering upstream and downstream process development, bioanalytical tools for critical quality attribute monitoring, to scale-up and tech transfer. iBET also hosts satellite laboratories of major pharmaceutical companies and serves as an incubation platform for start-up/spin-off companies. iBET is driven by its innovative and agile culture of continuous improvement and a strong sense of ambition, ownership and commitment in developing and delivering the best solutions to our stakeholders.  

News

Hovione and iBET announce the creation of ViSync Technologies, an innovative new company that will develop solutions for unmet needs in cell and gene therapy

May 09, 2024

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at gmp-journal.com  

Article

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024